Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

Investors may be wary of CONCORDBIO as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 6.168000
forwardPE 30.318136
debtToEquity 0.164000
earningsGrowth 0.478000
revenueGrowth 0.348000
grossMargins 0.651910
operatingMargins 0.408960
trailingEps 35.560000
forwardEps 0.000000

With a current ratio 6.168, CONCORDBIO demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
CONCORDBIO's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
Positive gross and operating margins for CONCORDBIO demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

CONCORDBIO's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Insider Transactions:

Insider Transactions for CONCORDBIO
Insider Transactions for CONCORDBIO


2 transactions to sell CONCORDBIO occurred, with market price at 1583.050048828125.The period under consideration saw no sell transactions.The higher number of buys versus sells near CONCORDBIO's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


Analysts' recent buy bias toward Concord Biotech Limited suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see Concord Biotech Limited as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.